Alkol ve Madde Kullanım Bozukluğunun Nörobiyolojisi
Özet
Bu çalışma, alkol ve madde kullanım bozukluğunun patofizyolojisini nörobiyolojik bir yaklaşımla inceleyerek, bağımlılığın gelişimi ve sürdürülmesinde rol oynayan temel beyin mekanizmaları ile nörotransmitter sistemlerini kapsamlı bir şekilde ele almaktadır. Uzm. Dr. Mustafa Çağrı Yıldız tarafından kaleme alınan metinde, tekrarlayan alkol veya madde kullanımının beyin işlevlerinde ve ödül sisteminde (mezolimbik dopamin yolağı) kalıcı nöroadaptif değişikliklere ve yeniden şekillenmelere yol açtığı vurgulanmaktadır. Bağımlılığın erken ve geç dönemlerinde pozitif ve negatif pekiştireçlerin ortaklaşa rol oynadığı ve bilişsel inhibisyon kontrolünün zayıfladığı belirtilmektedir. Kitapta, sürecin merkezinde yer alan dopamin başta olmak üzere; dürtüsellik kontrolüyle ilişkili serotonin, stres yanıtlarını düzenleyen norepinefrin, haz duygusuyla bağlantılı endojen opioidler ve endokannabinoidler ile temel uyarıcı/engelleyici moleküller olan glutamat ve GABA sistemleri detaylı olarak analiz edilmektedir. Sonuç olarak, kronik bir nörogelişimsel ve genetik rahatsızlık olan bağımlılığın tedavisinde, bu karmaşık nörokimyasal mekanizmaların ve reseptör alt tiplerinin (D1, D2, 5-HT1b vb.) tam olarak anlaşılmasının daha başarılı ve güncel tedavi yaklaşımlarının geliştirilmesine olanak tanıyacağı savunulmaktadır.
This study examines the pathophysiology of alcohol and substance use disorders through a neurobiological approach, comprehensively analyzing the core brain mechanisms and neurotransmitter systems involved in the development and maintenance of addiction. Written by Specialist Dr. Mustafa Çağrı Yıldız, the text emphasizes that recurrent alcohol or substance use causes permanent neuroadaptive alterations and remodeling in brain functions and the reward system, specifically the mesolimbic dopamine pathway. It notes that positive and negative reinforcers interactively contribute to the early and late stages of addiction, leading to an impairment in cognitive inhibitory control. The book provides a detailed analysis of dopamine, which lies at the center of this process, alongside serotonin associated with impulsivity control, norepinephrine regulating stress responses, endogenous opioids and endocannabinoids linked to pleasure, and glutamate and GABA, the fundamental excitatory and inhibitory molecules. In conclusion, it is argued that understanding these intricate neurochemical mechanisms and receptor subtypes (such as D1, D2, and 5-HT1b) in addiction—which is characterized as a chronic neurodevelopmental and genetic disorder—will enable the formulation of updated and more successful therapeutic strategies.
Referanslar
Heilig M, MacKillop J, Martinez D (September 2021). "Addiction as a brain disease revised: why it still matters, and the need for consilience, Neuropsychopharmacology volume 46, pages1715–1723 (2021)
Washburn DA (2016). "The Stroop effect at 80: The competition between stimulus control and cognitive control". J Exp Anal Behav. 105 (1): 3–13. doi:10.1002/jeab.194
Diamond A (2013). “ Executive functions”. Annu Rev Psychol. 64: 135-68. Doi: 10.1146/annurev-psych-113011-143750
Banerjee N (2014) Neurotransmitters in alcoholism: a review of neurobiological and genetic studies. Indian J Hum Genet 20:20–31.
Nestler EJ, Hyman SE, Holtzman DM, Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. 3rd ed. NY: McGraw-Hill Medical; 2015.
MacNicol B. (2017). The biology of addiction. Canadian Journal of Anesthesia/Journal canadien d'anesthésie, 64(2), 141-148.
Miendlarzewska EA, Bavelier D, Schwartz S (2016). Influence of reward motivation on human declarative memory. Neuroscience & Biobehavioral Reviews, 61, 156-176.
Akgün H. (2019), Farmasötik ve Medisinal Kimya (second edit) Ankara: Hacettepe Üniversitesi Yayınları
Goodman A (2008). Neurobiology of addiction: An integrative review. Biochemical pharmacology, 75(1), 266-322.
Kaya E. (2019), Bağımlılığın patofizyolojisi. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi, 6(3), 166-170.
Volkow ND, Fowler JS, Wang GJ (2003). The addicted human brain: insights from imaging studies. The Journal of clinical investigation, 111(10), 1444-1451.
Uhl GR, Koob GF, Cable J (2019). The neurobiology of addiction. Annals of the New York Academy of Sciences, 1451(1), 5-28.
Wise RA, Robble MA (2020). Dopamine and addiction. Annual review of psychology, 71, 79-106.
Grant JE, Schreiber L, Harvanko AM (2012). Neurobiology of addiction: Support for a syndrome model of addiction.
Berker B, Çakmak T, Koçak AÖ, Selamoğlu (2012). Serotonin ve insan sağlığı, Başkent Üniversitesi Sempozyum Bildirisi, 2012 Ankara 1-17.
Roy A, Linnoila M (1989). CSF studies on alcoholism and related behaviours. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 13(3-4), 505-511.
Thibaut, F. (2022). Anxiety disorders: a review of current literature. Dialogues in clinical neuroscience, 93-97
Andrews PW, Bharwani A, Lee KR (2015). Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neuroscience & Biobehavioral Reviews, 51, 164-188.
Kenna GA (2010). Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Current pharmaceutical design, 16(19), 2126–2135.
Moore RY, Bloom FE (1979). Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annual review of neuroscience, 2(1), 113-168.
Nestler EJ (2001). Molecular basis of long-term plasticity underlying addiction. Nature reviews neuroscience, 2(2), 119-128.
Leeman RF, Grant JE, Potenza MN (2009). Behavioral and neurological foundations for the moral and legal implications of intoxication, addictive behaviors and disinhibition. Behavioral sciences & the law, 27(2), 237–259.
Linnoila M, Mefford I, Nutt D (1987). Alcohol withdrawal and noradrenergic function. Annals of internal medicine, 107(6), 875–889.
Pert CB, Snyder SH (1973). Opiate receptor: demonstration in nervous tissue. Science (New York, N.Y.), 179(4077), 1011–1014.
Roberts JA, Koob FG, Neurobiyology of addiction (2019), Clinical Obstetrics and gynecology, Volume 62, Number 1, 118–127
Onay A (2020). Kenevir, Cannabis sativa L. (first edit) Ankara: Palme Yayınevi.
Büyüker MS, Gürbüz S, Uzunoğlu A (2020). Endojen opioidler ve endojen kannabinoidlerin epigenetik mekanizmaları. Tıp ve Sağlık Araştırmaları Teori, Yöntem, Uygulama Dergisi 7-26
Hill MN, Patel S, Carrier EJ (2005). Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology, 30(3), 508-515.
Bonci A, Bernardi G, Grillner P (2003). The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction. Trends in pharmacological sciences, 24(4), 172-177.
Tran VT, Snyder SH, Major LF (1981). GABA receptors are increased in brains of alcoholics. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 9(3), 289-292.
Johnston GAR (1996). GABAA receptor pharmacology. Pharmacology & therapeutics, 69(3), 173-198.
Koob GF (2004). A role for GABA mechanisms in the motivational effects of alcohol. Biochem Pharmacol 68:1515–1525.
